Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Trans R Soc Trop Med Hyg. 2012 Apr;106(4):267-9. doi: 10.1016/j.trstmh.2011.12.008. Epub 2012 Feb 14.
Chemotherapy can cause immunosuppression, which may trigger latent intestinal parasitic infections in stools to emerge. This study investigated whether intestinal parasites can emerge as opportunistic infections in breast and colorectal cancer patients (n=46 and n=15, respectively) undergoing chemotherapy treatment. Breast cancer patients were receiving a 5-fluorouracil/epirubicin/cyclophosphamide (FEC) regimen (6 chemotherapy cycles), and colorectal cancer patients were receiving either an oxaliplatin/5-fluorouracil/folinic acid (FOLFOX) regimen (12 cycles) or a 5-fluorouracil/folinic acid (Mayo) regimen (6 cycles). Patients had Blastocystis hominis and microsporidia infections that were only present during the intermediate chemotherapy cycles. Thus, cancer patients undergoing chemotherapy should be screened repeatedly for intestinal parasites, namely B. hominis and microsporidia, as they may reduce the efficacy of chemotherapy treatments.
化疗会引起免疫抑制,可能会导致粪便中潜伏的肠道寄生虫感染显现。本研究调查了肠道寄生虫是否会在接受化疗的乳腺癌和结直肠癌患者(分别为 46 例和 15 例)中作为机会性感染出现。乳腺癌患者接受氟尿嘧啶/表柔比星/环磷酰胺(FEC)方案(6 个化疗周期),结直肠癌患者接受奥沙利铂/氟尿嘧啶/亚叶酸(FOLFOX)方案(12 个周期)或氟尿嘧啶/亚叶酸(Mayo)方案(6 个周期)。患者在中间化疗周期中存在人芽囊原虫和微孢子虫感染。因此,接受化疗的癌症患者应反复筛查肠道寄生虫,即人芽囊原虫和微孢子虫,因为它们可能会降低化疗的疗效。